Open Access

Aberrant promoter methylation of cancer-related genes in human breast cancer

  • Authors:
    • Liang Wu
    • Ye Shen
    • Xianzhen Peng
    • Simin Zhang
    • Ming Wang
    • Guisheng Xu
    • Xianzhi Zheng
    • Jianming Wang
    • Cheng Lu
  • View Affiliations

  • Published online on: November 4, 2016     https://doi.org/10.3892/ol.2016.5351
  • Pages: 5145-5155
  • Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The clinical relevance of aberrant DNA methylation is being increasingly recognized in breast cancer. The present study aimed to evaluate the promoter methylation status of seven candidate genes and to explore their potential use as a biomarker for the diagnosis of breast cancer. A total of 70 Chinese patients with breast cancer were recruited, and matched with 20 patients with benign breast disease (BBD). Methylation‑specific polymerase chain reaction was performed to measure the methylation status of selected genes. The protein expression of candidate genes was determined by immunohistochemistry. Hypermethylation of Breast cancer 1, early onset; DNA repair associated (BRCA1), glutathione S-transferase pi 1 (GSTP1), cyclin dependent kinase inhibitor 2A, O-6-methylguanine-DNA methyltransferase, phosphatase and tensin homolog, retinoic acid receptor beta 2 and cyclin D2 was observed to be more common in cancerous tissues (24.3, 31.4, 40.0, 27.1, 48.6, 55.7 and 67.1%, respectively) as compared with BBD controls (0.0, 0.0, 20.0, 25.0, 40.0, 40.0 and 45.0%, respectively). Immunohistochemical analysis demonstrated a correlation between the methylation of the target gene and downregulation of protein expression. When BRCA1 and GSTP1 were combined as the biomarker, the area under the receiver operating characteristic curve reached 0.721 (95% confidence interval, 0.616‑0.827). The present findings indicated that promoter methylation of cancer‑related genes was frequently observed in patients with breast cancer and was associated with various clinical features. Hypermethylation of BRCA1 and GSTP1 may be used as promising biomarkers for breast cancer.
View Figures
View References

Related Articles

Journal Cover

December-2016
Volume 12 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wu L, Shen Y, Peng X, Zhang S, Wang M, Xu G, Zheng X, Wang J and Lu C: Aberrant promoter methylation of cancer-related genes in human breast cancer. Oncol Lett 12: 5145-5155, 2016.
APA
Wu, L., Shen, Y., Peng, X., Zhang, S., Wang, M., Xu, G. ... Lu, C. (2016). Aberrant promoter methylation of cancer-related genes in human breast cancer. Oncology Letters, 12, 5145-5155. https://doi.org/10.3892/ol.2016.5351
MLA
Wu, L., Shen, Y., Peng, X., Zhang, S., Wang, M., Xu, G., Zheng, X., Wang, J., Lu, C."Aberrant promoter methylation of cancer-related genes in human breast cancer". Oncology Letters 12.6 (2016): 5145-5155.
Chicago
Wu, L., Shen, Y., Peng, X., Zhang, S., Wang, M., Xu, G., Zheng, X., Wang, J., Lu, C."Aberrant promoter methylation of cancer-related genes in human breast cancer". Oncology Letters 12, no. 6 (2016): 5145-5155. https://doi.org/10.3892/ol.2016.5351